PE20230389A1 - Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas - Google Patents

Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas

Info

Publication number
PE20230389A1
PE20230389A1 PE2022002763A PE2022002763A PE20230389A1 PE 20230389 A1 PE20230389 A1 PE 20230389A1 PE 2022002763 A PE2022002763 A PE 2022002763A PE 2022002763 A PE2022002763 A PE 2022002763A PE 20230389 A1 PE20230389 A1 PE 20230389A1
Authority
PE
Peru
Prior art keywords
sec
lcdr2
lcdr3
hcdr2
hcdr3
Prior art date
Application number
PE2022002763A
Other languages
English (en)
Inventor
Raymond Brittingham
Fang Yi
Scott R Brodeur
Rajkumar Ganesan
Jaclyn Hoover
Steven A Jacobs
Colleen M Kane
Sanjaya Singh
Adam Zwolak
Triveni K Bhatt
Michael Dennis Feldkamp
Sherry Lynn Laporte
Jinquan Luo
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20230389A1 publication Critical patent/PE20230389A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una proteina aislada que comprende un dominio de union al antigeno que se une al cumulo de diferenciacion 3? (CD3?), en donde el dominio de union al antigeno que se une a CD3? comprende: a. una region determinante de complementariedad de cadena pesada (HCDR) 1, una HCDR2 y una HCDR3 de una region variable de cadena pesada (VH) de la sec. con num. de ident.: 23 y una region determinante de complementariedad de cadena ligera (LCDR) 1, una LCDR2 y una LCDR3 de una region variable de cadena ligera (VL) de la sec. con num. de ident.: 24; b. la HCDR1, la HCDR2 y la HCDR3 de la VH de la sec. con num. de ident.: 23 y la LCDR1, la LCDR2 y la LCDR3 de la VL de la sec. con num. de ident.: 27; c. la HCDR1, la HCDR2 y la HCDR3 de la VH de la sec. con num. de ident.: 23 y la LCDR1, la LCDR2 y la LCDR3 de la VL de la sec. con num. de ident.: 28; d. la HCDR1, la HCDR2 y la HCDR3 de la VH de la sec. con num. de ident.: 23 y la LCDR1, la LCDR2 y la LCDR3 de la VL de la sec. con num. de ident.: 29; o e. la HCDR1, la HCDR2 y la HCDR3 de la VH de la sec. con num. de ident.: 23 y la LCDR1, la LCDR2 y la LCDR3 de la VL de la sec. con num. de ident.: 30.
PE2022002763A 2020-05-27 2021-05-26 Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas PE20230389A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063030448P 2020-05-27 2020-05-27
US202063057958P 2020-07-29 2020-07-29
US202063094931P 2020-10-22 2020-10-22
PCT/IB2021/054582 WO2021240388A1 (en) 2020-05-27 2021-05-26 Proteins comprising cd3 antigen binding domains and uses thereof

Publications (1)

Publication Number Publication Date
PE20230389A1 true PE20230389A1 (es) 2023-03-06

Family

ID=76269770

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002763A PE20230389A1 (es) 2020-05-27 2021-05-26 Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas

Country Status (18)

Country Link
US (1) US20220411504A1 (es)
EP (1) EP4157459A1 (es)
JP (1) JP2023528350A (es)
KR (1) KR20230017841A (es)
CN (1) CN116249714A (es)
AU (1) AU2021281134A1 (es)
BR (1) BR112022023978A2 (es)
CA (1) CA3184189A1 (es)
CL (1) CL2022003320A1 (es)
CO (1) CO2022017056A2 (es)
CR (1) CR20220594A (es)
DO (1) DOP2022000256A (es)
EC (1) ECSP22096235A (es)
IL (1) IL298444A (es)
MX (1) MX2022014938A (es)
PE (1) PE20230389A1 (es)
TW (1) TW202210510A (es)
WO (1) WO2021240388A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023530083A (ja) * 2020-06-11 2023-07-13 ティゾナ セラピューティクス Ｈｌａ－ｇ及び別の抗原に対して結合特異性を有する二重特異性免疫細胞エンゲージャー
WO2024092038A2 (en) * 2022-10-25 2024-05-02 Ablexis, Llc Anti-cd3 antibodies
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
WO2024188965A1 (en) * 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024188966A1 (en) * 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4‑1bb (cd137) agonist

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
RU2451682C2 (ru) 2006-12-18 2012-05-27 Ариджен Фармасьютикалз, Инк. ПРЕПАРАТ ПРОТИВ Helicobacter pylori, ИНГИБИРУЮЩИЙ СЕКРЕЦИЮ ЖЕЛУДОЧНОГО СОКА
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9580491B2 (en) 2010-03-31 2017-02-28 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
EP3674320A3 (en) 2011-10-27 2020-08-12 Genmab A/S Production of heterodimeric proteins
EP2771037B1 (en) 2011-10-28 2016-08-03 Fredax AB Therapeutic agents and uses thereof
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
SI2794905T1 (sl) 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
AU2013249985B2 (en) 2012-04-20 2017-11-23 Merus N.V. Methods and means for the production of Ig-like molecules
PT2931030T (pt) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
CA2907140A1 (en) 2013-03-15 2014-09-25 Janssen Biotech, Inc. Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
KR102442738B1 (ko) 2013-11-19 2022-09-15 프레닥스 에이비 인간화된 안티 칼리크레인-2 항체
RU2016151235A (ru) * 2014-05-28 2018-06-28 Ф. Хоффманн-Ля Рош Аг Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус
PT3247725T (pt) * 2015-01-23 2020-10-07 Sanofi Sa Anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam de forma biespecífica a cd3 e/ou a cd123
WO2017027392A1 (en) * 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
WO2018060301A1 (en) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Bispecific antibodies against cd3
EP3668898B1 (en) * 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
US11440962B2 (en) * 2017-09-21 2022-09-13 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
EP3684816B1 (en) 2017-09-22 2024-05-29 Kite Pharma, Inc. Chimeric polypeptides and uses thereof
WO2019133761A1 (en) * 2017-12-27 2019-07-04 Teneobio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
AU2019235523A1 (en) * 2018-03-14 2020-10-29 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof
CR20200568A (es) * 2018-05-24 2021-02-26 Janssen Biotech Inc Antcuerpos anti-cd3 y usos de estos
CR20220025A (es) * 2019-07-26 2022-05-04 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos

Also Published As

Publication number Publication date
AU2021281134A1 (en) 2023-02-09
US20220411504A1 (en) 2022-12-29
MX2022014938A (es) 2023-03-06
KR20230017841A (ko) 2023-02-06
ECSP22096235A (es) 2023-01-31
CL2022003320A1 (es) 2023-02-03
BR112022023978A2 (pt) 2023-02-07
CN116249714A (zh) 2023-06-09
EP4157459A1 (en) 2023-04-05
WO2021240388A1 (en) 2021-12-02
JP2023528350A (ja) 2023-07-04
CR20220594A (es) 2023-01-17
CA3184189A1 (en) 2021-12-02
IL298444A (en) 2023-01-01
TW202210510A (zh) 2022-03-16
CO2022017056A2 (es) 2022-12-09
DOP2022000256A (es) 2023-03-15

Similar Documents

Publication Publication Date Title
PE20230389A1 (es) Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
IL277242B1 (en) Antibodies that bind cd39 and uses thereof
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
CO6230999A2 (es) Anticuerpo anti-esclerostina
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
HRP20160485T1 (hr) Anti-mezotelinska protutijela i njihova uporaba
NZ583605A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
NZ740221A (en) St2l antagonists and methods of use
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
PE20221282A1 (es) Anticuerpos que se unen a hla-a2/mage-a4
AR123083A1 (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
RU2018120695A (ru) Связывающие молекулы, специфичные в отношении asct2, и их применения